

191D3
1E4
7B2
NC23
15H8
NC41
NC39
15B3
202A5
Numax Fab
OD 450 nm
0.0
0.4
0.8
1.2
[M]
10-11
10-10
10-9
10-8
10-7
10-6

Figure 1



7B2
RSV400
15H8
RSV404
NC41
RSV116
RSV407
OD 450 nm
2.0
1.5
1.0
0.5
0.0
10-11
10-10
10-9
10-8
10-7
10-6
[M]

Figure 2

Figure 3A




Long
OD450-620
1.2
1.0
0.8
0.6
0.4
0.2
0.0
-5
-4
-3
-2
-1
0
1
µM
RSV-B-1
7B2
RSV106
RSV400
15B3
RSV205
RSV402
RSV403
Synagis Mab

Figure 3B


Long
OD450-620
1.0
0.8
0.6
0.4
0.2
0.0
-6
-5
-4
-3
-2
-1
0
1
µM
RSV-B-1
OD450-620
1.0
0.8
0.6
0.4
0.2
0.0
-5
-4
-3
-2
-1
0
1
2
µM
15H8
RSV404
NC41
RSV116
RSV407
Numax Fab
Synagis



7B2 Long
7B2 R7C2/11
7B2 R7C2/1
7B2 R7.936/4
% Viral antigen
120
100
80
60
40
20
0
10-9
10-8
10-7
10-6
10-5
[M]

Figure 4A



15H8 Long
15H8 R7C2/11
15H8 R7C2/1
15H8 R7.936/4
% Viral antigen
120
100
80
60
40
20
0
10-9
10-8
10-7
10-6
10-5
[M]

Figure 4B



NC41 Long
NC41 R7C2/11
NC41 R7C2/1
NC41 R7.936/4
% Viral antigen
120
100
80
60
40
20
0
10-9
10-8
10-7
10-6
10-5
[M]

Figure 4C



RSV400 Long
RSV400 R7C2/11
RSV400 R7C2/1
RSV400 R7.936/4
% Viral antigen
120
100
80
60
40
20
0
10-7
10-8
10-9
10-10
10-11
[M]

Figure 4D



RSV404 Long
RSV404 R7C2/11
RSV404 R7C2/1
RSV404 R7.936/4
% Viral antigen
120
100
80
60
40
20
0
10-11
10-10
10-9
10-8
10-7
[M]

Figure 4E



RSV407 Long
RSV407 R7C2/11
RSV407 R7C2/1
RSV407 R7.936/4
% Viral antigen
120
100
80
60
40
20
0
10-11
10-10
10-9
10-8
10-7
[M]

Figure 4F



RSV403 Long
RSV403 R7C2/11
RSV403 R7C2/1
RSV403 R7.936/4
% Viral antigen
120
100
80
60
40
20
0
10-11
10-10
10-9
10-8
10-7
[M]

Figure 4G

Figure 5



Long
OD450-620
1.0
0.8
0.6
0.4
0.2
0.0
-6
-5
-4
-3
-2
-1
0
1
µM
B-1
OD450-620
1.0
0.8
0.6
0.4
0.2
0.0
-5
-4
-3
-2
-1
0
µM
NC41
RSV408
RSV409
RSV407
RSV410
Synagis

Figure 6

	V5L	A14P	S19R	I20L	E44G	G54D	A74S	G78L	A83R	D85E	R105Q	Q108L	# mutations
NC41v01	I	p	r	l	g	.	.	l	.	e	q	l	9
NC41v02	I	p	r	.	g	.	s	l	.	e	q	l	9
NC41v03	I	p	r	.	g	.	s	l	r	e	q	l	10
NC41v04	I	p	.	.	g	.	s	l	r	.	q	l	8
NC41v05	I	p	.	.	g	.	s	l	.	e	q	l	8
NC41v06	I	p	r	l	g	d	.	l	r	e	q	l	11
NC41v07	I	p	.	.	g	.	.	l	.	.	q	l	6
NC41v08	I	p	.	.	g	.	.	.	r	e	q	l	7
NC41v09	I	p	.	.	g	.	s	.	r	.	q	l	7
NC41v10	I	p	.	.	g	.	.	.	.	.	q	l	5
NC41v11	I	.	.	.	g	.	.	.	.	.	q	l	4
NC41v12	I	p	.	.	.	.	.	.	.	.	q	l	4
NC41v13	I	p	r	l	g	.	.	.	.	e	q	l	8
NC41v14	I	p	r	l	g	.	s	l	.	e	q	l	10
NC41v15	I	.	r	l	g	.	.	l	.	e	q	l	8
NC41v16	I	p	r	l	.	.	.	l	.	e	q	l	8
NC41v17	I	p	r	l	g	.	s	l	r	e	q	l	11
NC41v18	I	p	r	l	g	d	s	l	r	e	q	l	12

Figure 7

	FR1	CDR1	FR2	CDR2
NC41	evqlvesggglvqaggslsiscaasggsls	NYVLG	wfrqapgkerefva	AINWRGDITIGPPNVEG
NC41v01	evqllesggglvqpggslrlscaasggsls	NYVLG	wfrqapgkgrefva	AINWRGDITIGPPNVEG
NC41v02	evqllesggglvqpggslriscaasggsls	NYVLG	wfrqapgkgrefva	AINWRGDITIGPPNVEG
NC41v03	evqllesggglvqpggslriscaasggsls	NYVLG	wfrqapgkgrefva	AINWRGDITIGPPNVEG
NC41v04	evqllesggglvqpggslsiscaasggsls	NYVLG	wfrqapgkgrefva	AINWRGDITIGPPNVEG
NC41v05	evqllesggglvqpggslsiscaasggsls	NYVLG	wfrqapgkgrefva	AINWRGDITIGPPNVEG
NC41v06	evqllesggglvqpggslrlscaasggsls	NYVLG	wfrqapgkgrefva	AINWRDDITIGPPNVEG
NC41v07	evqllesggglvqpggslsiscaasggsls	NYVLG	wfrqapgkgrefva	AINWRGDITIGPPNVEG
NC41v08	evqllesggglvqpggslsiscaasggsls	NYVLG	wfrqapgkgrefva	AINWRGDITIGPPNVEG
NC41v09	evqllesggglvqpggslsiscaasggsls	NYVLG	wfrqapgkgrefva	AINWRGDITIGPPNVEG
NC41v10	evqllesggglvqpggslsiscaasggsls	NYVLG	wfrqapgkgrefva	AINWRGDITIGPPNVEG
NC41v11	evqllesggglvqaggslsiscaasggsls	NYVLG	wfrqapgkgrefva	AINWRGDITIGPPNVEG
NC41v12	evqllesggglvqpggslsiscaasggsls	NYVLG	wfrqapgkerefva	AINWRGDITIGPPNVEG
NC41v13	evqllesggglvqpggslrlscaasggsls	NYVLG	wfrqapgkgrefva	AINWRGDITIGPPNVEG
NC41v14	evqllesggglvqpggslrlscaasggsls	NYVLG	wfrqapgkgrefva	AINWRGDITIGPPNVEG
NC41v15	evqllesggglvqaggslrlscaasggsls	NYVLG	wfrqapgkgrefva	AINWRGDITIGPPNVEG
NC41v17	evqllesggglvqpggslrlscaasggsls	NYVLG	wfrqapgkgrefva	AINWRGDITIGPPNVEG
NC41v18	evqllesggglvqpggslrlscaasggsls	NYVLG	wfrqapgkgrefva	AINWRDDITIGPPNVEG

Figure 7: Continued

	FR3	CDR3	FR4
NC41	rftisrdnakntgylqmnslapddtavyycga	GTPLNPGAYIYDWSYDY	wgrgtqvtvss
NC41v01	rftisrdnakntlylqmnslapedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v02	rftisrdnsknt**l**ylqmnslapedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v03	rftisrdnsknt**l**ylqmnsl**r**pedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v04	rftisrdnsknt**l**ylqmnsl**r**pddtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v05	rftisrdnsknt**l**ylqmnslapedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v06	rftisrdnakntlylqmnsl**r**pedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v07	rftisrdnakntlylqmnslapddtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v08	rftisrdnakntlylqmnsl**r**pedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v09	rftisrdnsknt**l**ylqmnsl**r**pddtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v10	rftisrdnakntgylqmnslapddtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v11	rftisrdnakntgylqmnslapddtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v12	rftisrdnakntgylqmnslapddtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v13	rftisrdnakntgylqmnslapedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v14	rftisrdnsknt**l**ylqmnslapedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v15	rftisrdnakntlylqmnslapedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v17	rftisrdnsknt**l**ylqmnsl**r**pedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss
NC41v18	rftisrdnsknt**l**ylqmnsl**r**pedtavyycga	GTPLNPGAYIYDWSYDY	wgqgtlvtvss

Figure 8A




RSV-Long
OD450-620
0.8
0.7
0.6
0.5
0.4
0.3
0.2
10-6 10-5 10-4 10-3 10-2 10-1 100 101
µM
RSV-B-1
OD450-620
0.7
0.6
0.5
0.4
0.3
0.2
10-5 10-4 10-3 10-2 10-1 100 101
µM
1A4
1A4v3
1A4v6
1A4v18
RSV407
RSV414
RSV426
Synagis

Figure 8B


Long
% Viral antigen
1.0
0.8
0.6
0.4
0.2
10^{-6} 10^{-5} 10^{-4} 10^{-3} 10^{-2} 10^{-1} 10^{0}
µM
B-1
OD450-620
0.7
0.6
0.5
0.4
0.3
0.2
0.1
10^{-5} 10^{-4} 10^{-3} 10^{-2} 10^{-1} 10^{0}
µM
RSV407
RSV414
RSV426
RSV427
Synagis



Long (A strain)
RSV407
RSV434
OD450-620nm
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0.0001
0.001
0.01
0.1
1
10
100
[NB] in nM

Figure 9A



B strain
RSV407
RSV434
OD450-620nm
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
0.0001
0.001
0.01
0.1
1
10
100
[NB] in nM

Figure 9B



Lung lavage virus titers
Log10 PFU/g lung
0
1
2
3
4
5
6
PBS
5mg/ml
1mg/ml
0.2mg/ml
0.04mg/ml
*
*
*
TREATMENT

Figure 10A



Lung lavage q-RT-PCR
FOLD REDUCTION IN MEAN C_T VALUES
90
80
70
60
50
40
30
20
10
0
5mg/ml
1mg/ml
0.2mg/ml
0.04mg/ml
TREATMENT
*
*
*
*

Figure 10B



MEAN (±SD) VIRUS TITER (log10 PFU/g lung)
0
1
2
3
4
5
6
* P<0.05 v Untreated
*
*
*
*
0
1
2
3.9
20.8
TREATMENT (mean mg/kg)

Figure 11A



MEAN (±SD) VIRUS TITER (log10 PFU/g lung)
0
1
2
3
4
5
6
* P<0.05 v Untreated
*
*
*
*
0
1
2
3.9
20.8
TREATMENT (mean mg/kg)

Figure 11B